ACE2 Protein, Human, Recombinant (His Tag), Biotinylated

1/2
Price:
Size:
Number:

ACE2 Protein, Human, Recombinant (His Tag), Biotinylated: Product Information

Purity
> 95 % as determined by SDS-PAGE.
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
Activity
Measured by its binding ability in a functional ELISA. Immobilized 2019-nCoV Spike Protein (RBD, mFc Tag) (Cat: 40592-V05H) at 2 μg/mL (100 μL/well) can bind human ACE2 protein (His tag), Biotinylated, the EC50 of ACE2, Biotinylated is 10-35 ng/mL.
Protein Construction
A DNA sequence encoding the human ACE2 (NP_068576.1) (Met1-Ser740) was expressed with a polyhistidine tag at the C-terminus. The purified protein was biotinylated in vitro.
Accession#
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
Gln 18
Molecule Mass
The recombinant human ACE2 consists of 734 amino acids and predicts a molecular mass of 85.1 kDa.
Formulation
Lyophilized from sterile PBS, pH 7.4.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

ACE2 Protein, Human, Recombinant (His Tag), Biotinylated: Images

Measured by its binding ability in a functional ELISA. Immobilized 2019-nCoV Spike Protein (RBD, mFc Tag) (40592-V05H) at 2 μg/mL (100 μL/well) can bind human ACE2 protein (His tag), Biotinylated, the EC50 of ACE2, Biotinylated is 10-35 ng/mL.

ACE2 Protein, Human, Recombinant (His Tag), Biotinylated: Synonyms

ACEH Protein, Human

ACE2 Background Information

Angiotensin-converting enzyme 2 (ACE2), a first homolog of ACE, regulates the renin angiotensin system (RAS) by counterbalancing ACE activity. Accumulating evidence in recent years has demonstrated a physiological and pathological role of ACE2 in the cardiovascular, renal and respiratory systems. ACE2 also has an important role in blood pressure control. This enzyme, an homolog of ACE, hydrolyzes angiotensin (Ang) I to produce Ang-(1-9), which is subsequently converted into Ang-(1-7) by a neutral endopeptidase and ACE. ACE2 releases Ang-(1-7) more efficiently than its catalysis of Ang-(1-9) by cleavage of Pro(7)-Phe(8) bound in Ang II. Thus, the major biologically active product of ACE2 is Ang-(1-7), which is considered to be a beneficial peptide of the RAS cascade in the cardiovascular system. A physiological role for ACE2 has been implicated in hypertension, cardiac function, heart function and diabetes, and as a receptor of the severe acute respiratory syndrome coronavirus. In the acute respiratory distress syndrome (ARDS), ACE, AngII, and AT1R promote the disease pathogenesis, whereas ACE2 and the AT2R protect from ARDS. Importantly, ACE2 has been identified as a key SARS-coronavirus receptor and plays a protective role in severe acute respiratory syndrome (SARS) pathogenesis. Furthermore, the recent explosion of research into the ACE2 homolog, collectrin, has revealed a new physiological function of ACE2 as an amino acid transporter, which explains the pathogenic role of gene mutations in Hartnup disorder. This review summarizes and discusses the recently unveiled roles for ACE2 in disease pathogenesis.
Full Name
angiotensin I converting enzyme 2
References
  • Koitka A, et al. (2008) Angiotensin converting enzyme 2 in the kidney. Clin Exp Pharmacol Physiol. 35(4): 420-5.
  • Raizada MK, et al. (2007) ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol. 50(2): 112-9.
  • Imai Y, et al. (2007) Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J. 74(3): 405-10.
  • Turner AJ, et al. (2004) ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 25(6): 291-4.
  • Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response
    Author
    Routhu, N;Gangadhara, S;Cheedarla, N;Shiferaw, A;Rahman, S;Sahoo, A;Shi, P;Menachery, V;Floyd, K;Fischinger, S;Atyeo, C;Alter, G;Suthar, M;Amara, R;
    Year
    2020
    Journal
    bioRxiv
  • Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice
    Author
    Liu, X;Drelich, A;Li, W;Chen, C;Sun, Z;Shi, M;Adams, C;Mellors, J;Tseng, C;Dimitrov, D;
    Year
    2020
    Journal
    Vaccine
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.